



Advancing New RNA Therapies Through a Modular Approach

The TransCode TTX platform for RNA cancer therapeutic development is modular by design, both at the level of the core nanoparticle and of the therapeutic loading. The size, charge, and surface chemistry of the core nanoparticle can be tuned to optimize the particles for the intended target and therapeutic load.

The therapeutic load can also be adapted to the specific application being developed, ranging from siRNAs, antisense oligonucleotides, and non-coding RNA mimics to mRNA-based cancer vaccines and CRISPR-based gene repair and replacement platforms.

The platform can further be used for developing RNA-targeted radiolabeled therapeutics and diagnostics and other custom products targeting known and novel biomarkers and other genetic elements as they are discovered and validated.

Design Engine for Customized Development of RNA Therapeutics In oncology and beyond

